# Task A02: Product Development Planning and Evaluation - The Lilly TB Drug Discovery Initiative

> **NIH NIH N02** · RESEARCH TRIANGLE INSTITUTE · 2021 · $550,116

## Abstract

The Non-clinical Services for Development of Interventional Agents for Infectious Diseases program provides services to facilitate preclinical product development of promising therapeutics for infectious disease-causing pathogens and/or toxins. Services include: preclinical product development planning and evaluation; lead identification and development; chemistry and GMP manufacturing; in vitro and in vivo preclinical microbiological, safety, toxicology and pharmacokinetics.

## Key facts

- **NIH application ID:** 10449070
- **Project number:** 272201800002I-P00002-759301900134-1
- **Recipient organization:** RESEARCH TRIANGLE INSTITUTE
- **Principal Investigator:** DIANA STEVENS
- **Activity code:** N02 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $550,116
- **Award type:** —
- **Project period:** 2019-08-31 → 2021-08-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10449070

## Citation

> US National Institutes of Health, RePORTER application 10449070, Task A02: Product Development Planning and Evaluation - The Lilly TB Drug Discovery Initiative (272201800002I-P00002-759301900134-1). Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/grant/nih/10449070. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*